Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7452-7462

  Daftarian, Pirouz ^a,b   Kaifer, Angel E ^e   Li, Wei ^e   Blomberg, Bonnie B ^a   Frasca, Daniela ^a   Roth, Felix ^a   Chowdhury, Raquibul ^a   Berg, Eric A ^f   Fishman, Jordan B ^f   Al Sayegh, Husain A ^c   Blackwelder, Pat ^c   Inverardi, Luca ^c   Perez, Victor L ^b   Lemmon, Vance ^d   Serafini, Paolo ^a,c,d  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Department of Biology   (United States)

^f 721st Century Biochemicals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA GENERATION 5 POLYAMIDOAMINE DENDRIMER CONJUGATE VACCINE; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BREAST ADENOCARCINOMA; CANCER SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; T CELL DEPLETION; T LYMPHOCYTE; TUMOR REJECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN-PRESENTING CELLS; CELL LINE, TUMOR; CELLS, CULTURED; DENDRIMERS; DNA; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEPTIDES; PROTEIN BINDING; STATIC ELECTRICITY; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES, DNA;

EID: 84255170451     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1766     Document Type: Article

References (32)

1. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164:4635-40. (Pubitemid 30238062)
2. Cappelletti M, Zampaglione I, Rizzuto G, Ciliberto G, La Monica N, Fattori E. Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. J Gene Med 2003;5:324-32. (Pubitemid 40310384)
3. Mennuni C, Calvaruso F, Facciabene A, Aurisicchio L, Storto M, Scarselli E, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005;117:444-55. (Pubitemid 41429568)
4. Rice J, Dossett ML, Ohl-en C, Buchan SL, Kendall TJ, Dunn SN, et al. DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire. Eur J Immunol 2008;38:2118-30.
5. Liu MA. Immunologic basis of vaccine vectors. Immunity 2010;33:504-15.
6. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010;28 Suppl 3:C25-36.
7. Pietersz GA, Tang CK, Apostolopoulos V. Structure and design of polycationic carriers for gene delivery. Mini Rev Med Chem 2006;6:1285-98. (Pubitemid 44890536)
8. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2009;109:49-87.
9. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174:1580-6.
10. Velappan N, Clements J, Kiss C, Valero-Aracama R, Pavlik P, Bradbury AR. Fluorescence linked immunosorbant assays using microtiter plates. J Immunol Methods 2008;336:135-41.
11. De Palma R, Marigo I, Del Galdo F, De Santo C, Serafini P, Cingarlini S, et al. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. Cancer Res 2004;64:8068-76. (Pubitemid 39446945)
12. Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, et al. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol 2003;171:6396-405. (Pubitemid 37532067)
13. Rabussay D. Applicator and electrode design for in vivo DNA delivery by electroporation. Methods Mol Biol 2008;423:35-59.
14. Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res 1998;18:79-92. (Pubitemid 28554760)
15. Kim D, Monie A, He L, Tsai YC, Hung CF, Wu TC. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther 2008;15:677-87. (Pubitemid 351524522)
16. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-61.
17. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-9. (Pubitemid 27078363)
18. Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, et al. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000;60:253-8. (Pubitemid 30070745)
19. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996;93:9730-5. (Pubitemid 26296677)
20. Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009;4:e7226.
21. Brumeanu TD, Casares S, Bot A, Bot S, Bona CA. Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus. J Virol 1997;71:5473-80. (Pubitemid 27258225)
22. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 2007;92:50-7. (Pubitemid 47096896)
23. Hung CF, Yang M, Wu TC. Modifying professional antigen-presenting cells to enhance DNA vaccine potency. Methods Mol Med 2006;127:199-220.
24. Jerome V, Graser A, Muller R, Kontermann RE, Konur A. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. J Immunother 2006;29:294-305. (Pubitemid 44297297)
25. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006;66:4904-12.
26. Nanni P, De Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983;1:373-80. (Pubitemid 14221672)
27. Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. Cancer Res 2002;62:4390-7. (Pubitemid 34827298)
28. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008;205:825-39. (Pubitemid 351549881)
29. Frelin L, Brass A, Ahlen G, Brenndorfer ED, Chen M, Sallberg M. Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans? Drug News Perspect 2010;23:647-53.
30. Wu CY, Monie A, Pang X, Hung CF, Wu TC. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci 2010;17:88.
31. Kim D, Monie A, Tsai YC, He L, Wang MC, Hung CF, et al. Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Ther 2008;15:1176-83.
32. Heegaard PM, Boas U, Sorensen NS. Dendrimers for vaccine and immunostimulatory uses. A review. Bioconjug Chem 2010;21:405-18.